Trials / Completed
CompletedNCT01359956
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma
Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma: Phase III Study
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 269 (actual)
- Sponsor
- National Cancer Institute, Naples · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluated two chemotherapy regimens with and without the addition of interferon in patients with advanced or recurrent melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dacarbazine | 900 mg / m2 every 3 weeks |
| DRUG | Fotemustine | 100 mg / m2 every 3 weeks |
| DRUG | Interferon Alfa-2b | 5 M units every 3 weeks |
Timeline
- Start date
- 2002-04-01
- Primary completion
- 2011-02-01
- Completion
- 2011-02-01
- First posted
- 2011-05-25
- Last updated
- 2023-04-11
- Results posted
- 2020-11-13
Source: ClinicalTrials.gov record NCT01359956. Inclusion in this directory is not an endorsement.